Rallybio Corp (RLYB)

PriceLoading quote

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

6 annual periodsNewest to oldest
202520242023202220212020
Revenue$858,000$636,000
Research & development$19.6M$41.5M$53.5M$40.7M$26.9M$17.6M
Operating expenses$33.9M$61.1M$78.9M$67.9M$45.6M$25.3M
Operating income−$33.1M−$60.5M−$78.9M−$67.9M−$45.6M−$25.3M
EBITDAderived−$33.0M−$60.4M−$78.8M−$67.7M−$45.5M−$25.2M
Net income−$9.0M−$57.8M−$74.6M−$66.7M−$47.0M−$26.4M
Basic EPSper diluted share-$1.59-$10.61-$1.84-$2.09-$1.84-$1.52
Diluted EPSper diluted share-$1.59-$10.61-$1.84-$2.09-$1.84-$1.52

Insider buys & sells

Jul 1, 2024Jun 30, 2026
Buys14$4.23M disclosed value
Sells (SEC code S)1$4.0K disclosed value
15 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
May 19, 2026Form 4ADAR1 Capital Management, LLC +1TenPercentOwnerBuyCommon Stock · indirect200$13.80$2.8K926.4K
May 19, 2026Form 4ADAR1 Capital Management, LLC +1TenPercentOwnerBuyCommon Stock · indirect10.0K$13.98$139.8K926.2K
May 18, 2026Form 4ADAR1 Capital Management, LLC +1TenPercentOwnerBuyCommon Stock · indirect6.0K$13.98$84.0K916.2K
May 15, 2026Form 4Schneeberger Daniel +1TenPercentOwnerBuyCommon Stock · indirect200$13.95$2.8K910.1K
May 15, 2026Form 4Schneeberger Daniel +1TenPercentOwnerBuyCommon Stock · indirect100$13.80$1.4K909.9K